BRIEF—Lieven Huysse handed CMO job at BioSenic

BioSenic, a Belgian biotech company specializing in serious autoimmune and inflammatory diseases and cell repair, has named Lieven Huysse, as permanent chief medical officer (CMO).

Dr Huysse will succeed Michel Wurm’s, who was given the CMO job temporarily to drive forward the development of platforms at the company, which was previously known as Bone Therapeutics.

Among Dr Huysse’s previous roles are CMO for Anaconda Biomed, senior director of medical affairs at Intrinsic Therapeutics and medical director for Menarini Group.

He said: “BioSenic is now driving late-stage clinical development of two highly innovative platforms, and currently targeting four indications with its cell therapy and arsenic trioxide platforms.

“As CMO, I will now be responsible for driving through clinical candidates that can impact a wide range of patients suffering from a variety of conditions and make a meaningful difference to the lives of a large number of patients.”